
Maurizio Scaltriti: What stands out at ESMO23 is the critical role that innovative trial design, early mechanistic studies and ongoing translational analysis play in informing treatment strategy
Maurizio Scaltriti, Vice President of Translational Medicine at AstraZenica, shared a post on LinkedIn:
“It’s great to be back at ESMO this year! Looking at the presentations across the board, what stands out is the critical role that innovative trial design, early mechanistic studies and ongoing translational analysis play in informing treatment strategy.
For example, paired pre- and post-treatment biopsies tell us about potential mechanisms of resistance and help select the patients most likely to benefit from combinations, whereas longitudinal ctDNA assessment during dose escalation/expansion helps us monitor treatment response as it happens. By interrogating tumor biology in this way, we also continue to improve our understanding of drug mechanisms of action, which is valuable in making clinical decisions.
At AstraZeneca we use next generation diagnostics, such as ctDNA, computational pathology and multi-omics to monitor biomarkers of response and enhance our ability to select patients for personalized treatment. We do this to ensure that patients with cancer receive the right treatment at the right time, which is critical for improving outcomes. Read more about how we are using ctDNA in our trials.”
For more information click here.
Source: Maurizio Scaltriti/LinkedIn.
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows